Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment). The SUPPORTS trial is being conducted at major transplant centers throughout the US, Europe, and Australia and is expected to complete in the second half of 2011.  The trial is the subject of a Special Protocol Assessment (SPA) agreement that the Company reached with the US Food and Drug Administration (FDA).

orBec® was the subject of two prior randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD. The first study was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, p-value 0.04).

orBec® represents a first-of-its-kind oral, locally acting thera
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... , June 17, 2013  A little known drug ... under scrutiny by the U.S. Supreme Court – and a ... issue could not have come at a better time for ... result from the Rx industry tactic are all too apparent ... of 50+ New Yorkers, state residents are in a near ...
(Date:6/17/2013)... PHILADELPHIA , June 17, 2013 ... support; program promoted through new ,Wake-Up Call, campaign ... Elsevier , a world-leading provider of scientific, technical ... the launch of EduCode ® Doc ... physicians and other practitioners. EduCode Doc Briefs is ...
(Date:6/17/2013)... , June 14, 2013 The law firm ... commenced what is believed to be the first suit in ... pancreatic cancer in the user of two common anti-diabetic drugs, ... Staten Island resident Robert Cataletto ... Pharmaceuticals, LLC, et al., E.D.N.Y. CV 13-3411. Mr. ...
Breaking Medicine Technology:Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3Elsevier Launches EduCode Doc Briefs to Help Physicians Implement ICD-10 2Elsevier Launches EduCode Doc Briefs to Help Physicians Implement ICD-10 3Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet 2
(Date:6/17/2013)... (PRWEB) June 17, 2013 "Do you think ... are texting, emailing or using your phone even with a ... warns it is just as dangerous as not using a ... those of you using Facebook, texting, emailing etc." ... and alters their reflexes that distract the brain, according to ...
(Date:6/17/2013)... New York, NY (PRWEB) June 17, 2013 ... Block O'Toole & Murphy, LLP are pleased to ... http://www.blockotoole.com/Attorneys/Stephen-J-Murphy.shtml ) and David L. Scher ( http://www.blockotoole.com/Attorneys/David-L-Scher.shtml ... radio station Z100 (100.3 FM) this Sunday, June ... Mr. Scher will be guests on Kevin Burke's ...
(Date:6/17/2013)... According to a June 11, 2013 ABC News article, titled ... surfaces about the negative effects of sun on the ... skin care routine, as the sun's rays can ... “I agree with the article's suggestions for the best way ... Epione Beverly Hills. “Apply a minimum of SPF 30, twenty ...
(Date:6/17/2013)... As da Vinci robot lawsuit ... Bernstein Liebhard LLP notes that a recent report aired ... the disturbing robotic surgery complications alleged to have been caused ... the June 14th broadcast revealed that the U.S. Food & ... da Vinci patients who suffered burns, cuts and infections since ...
(Date:6/17/2013)... 17, 2013 San Antonio Eye Center PA has ... St. has just opened up a new portion of the office, ... downtown optical shop over the years, and SA Eye Center has ... Center one step closer to providing patients with everything they need ... The downtown optical shop is the largest SA Eye Center in ...
Breaking Medicine News(10 mins):Health News:Dr. Bonnie Weil Warns Hands Free is Not a Life Saver, It Can Be Just as Much of a Distraction 2Health News:Injury Attorneys Block O'Toole & Murphy, LLP to Appear on Z100 Radio Show This Sunday to Discuss Their Support of St. Jude Children's Research Hospital 2Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 3Health News:San Antonio Eye Center PA Opens New Optical Shop 2
... Haiti , Jan. 19 One week later, ... of delivering aid in the aftermath of the Haiti ... aid is beginning to get through, the impact of the ... combined with a destroyed office and warehouse and the loss ...
... , JACKSONVILLE, Fla. and DES ... Inc. ( www.USPreventiveMedicine.com ) will partner with the Iowa Chronic Care ... not yet eligible for Medicare reduce health risks and live longer, ... equal amounts by a grant/cooperative agreement from the Centers for Disease ...
... PHILADELPHIA , Jan. 19 Independence Blue ... been promoted to chief marketing executive. Taylor will report to ... Independence Blue Cross. , As chief marketing executive, Taylor ... Cross (IBC) and two of the company,s third-party administrators:  Independence ...
... , , PHILADELPHIA , Jan. ... Paul A. Tufano has assumed an expanded role of senior ... continue to report to IBC president and CEO Joseph A. ... counsel since November 1999 when he joined IBC. , ...
... , ... Lindt Chocolate , the world,s leading producer of premium chocolate, announces it ... Autism program. For the second year, Lindt will honor ordinary individuals ... home or community.  The Lindt Unsung Heroes of Autism program is part ...
... Providence, RI New research at Rhode Island Hospital has ... brain tumors which, once diagnosed, offer a poor prognosis and ... naturally-occurring hormone combined with chemotherapy, researchers were able to inhibit ... study and their findings are published in the Journal ...
Cached Medicine News:Health News:Haiti Earthquake: One Week Later, Aid Agencies Facing Challenges 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 3Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 4Health News:Taylor Promoted to Independence Blue Cross Chief Marketing Executive 2Health News:Taylor Promoted to Independence Blue Cross Chief Marketing Executive 3Health News:Independence Blue Cross Announces New, Expanded Role For Key Executive 2Health News:Independence Blue Cross Announces New, Expanded Role For Key Executive 3Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 2Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 3Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 4Health News:Researchers find a treatment for deadly brain tumor 2
It provides cranial support in either supine or semi-sitting procedures....
Hudson cranial drill set which includes burr (9 mm), burr (14 mm), burr (16 mm), burr (22 mm), cerebellar extension, brace and sterilizing case....
Children's hospital hand drill, hexagonal handle, twist drill diameter 4.2 mm....
Hudson hand drill with extension piece....
Medicine Products: